Obesity Medical Science Liaison - Field Impact

Amgen Inc. (IR); Columbus (OH); Hybrid; USD 157,000 - 212,000; Full time

Job summary

Amgen Inc. in Cleveland, Ohio, seeks a Medical Science Liaison focused on obesity to serve as a primary scientific resource for Opinion Leaders (OLs) and Population Health Decision Makers (PHDMs), delivering data-driven insights to improve patient outcomes.

This field-based role reports to the Obesity MSL Field Director; it requires advanced degrees and strong communication, with a focus on engaging investigators, supporting sponsored and non-sponsored studies, and contributing to Amgen’s

Qualifications

• Doctorate or equivalent advanced degree in a life sciences field.
• Master’s degree with 3+ years in Medical Affairs; or Bachelor’s with 5 years in Medical Affairs.
• Experience in Medical Affairs within biotech/pharma is preferred.
• Strong scientific exchange and investigator engagement experience.

Responsibilities

• Act as primary scientific resource to Opinion Leaders and healthcare providers.
• Engage with investigators and sites to support the obesity pipeline.
• Communicate clinical and economic data to PHDMs and IDNs.
• Lead and participate in MSL projects and congress activities.
• Maintain clinical/scientific acumen with current data and trends.

Skills

Scientific communication

Stakeholder engagement

Collaborative teamwork

Clinical data interpretation

Education

Doctorate degree

Master’s degree in Medical Affairs

Bachelor’s degree in Life Sciences

Pharm.D., Ph.D., M.D. or D.O.

Tools

Veeva CRM

Job description

Amgen Inc. in Cleveland, Ohio, seeks a Medical Science Liaison focused on obesity to serve as a primary scientific resource for Opinion Leaders (OLs) and Population Health Decision Makers (PHDMs), delivering data-driven insights to improve patient outcomes.

This field-based role reports to the Obesity MSL Field Director; it requires advanced degrees and strong communication, with a focus on engaging investigators, supporting sponsored and non-sponsored studies, and contributing to Amgen’s